Start the conversation
The GWPH stock price soared more than 130% to $88.22 a share this morning (Monday) morning after GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH) announced positive phase 3 study results for its investigational cannabidiol drug, Epidiolex.
Epidiolex is designed to treat Dravet syndrome. Also known as severe myoclonic epilepsy of infancy (SMEI), Dravet syndrome is a type of epilepsy with often fatal seizures.